- Home
- IGMS vs ATRC Comparison
IGMS vs ATRC Comparison
Compare IGMS & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- ATRC
- Stock Information
- Founded
- IGMS 1993
- ATRC 2000
- Country
- IGMS United States
- ATRC United States
- Employees
- IGMS N/A
- ATRC N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- ATRC Medical/Dental Instruments
- Sector
- IGMS Health Care
- ATRC Health Care
- Exchange
- IGMS Nasdaq
- ATRC Nasdaq
- Market Cap
- IGMS 82.1M
- ATRC 1.6B
- IPO Year
- IGMS 2019
- ATRC 2005
- Fundamental
- Price
- IGMS $1.37
- ATRC $31.76
- Analyst Decision
- IGMS Hold
- ATRC Strong Buy
- Analyst Count
- IGMS 8
- ATRC 10
- Target Price
- IGMS $6.00
- ATRC $49.60
- AVG Volume (30 Days)
- IGMS 1.1M
- ATRC 424.4K
- Earning Date
- IGMS 08-13-2025
- ATRC 07-29-2025
- Dividend Yield
- IGMS N/A
- ATRC N/A
- EPS Growth
- IGMS N/A
- ATRC N/A
- EPS
- IGMS N/A
- ATRC N/A
- Revenue
- IGMS $2,681,000.00
- ATRC $480,076,000.00
- Revenue This Year
- IGMS $134.30
- ATRC $14.63
- Revenue Next Year
- IGMS $22.37
- ATRC $12.62
- P/E Ratio
- IGMS N/A
- ATRC N/A
- Revenue Growth
- IGMS 27.36
- ATRC 15.79
- 52 Week Low
- IGMS $0.92
- ATRC $20.20
- 52 Week High
- IGMS $22.50
- ATRC $43.11
- Technical
- Relative Strength Index (RSI)
- IGMS 59.58
- ATRC 44.34
- Support Level
- IGMS $1.12
- ATRC $30.85
- Resistance Level
- IGMS $1.39
- ATRC $33.15
- Average True Range (ATR)
- IGMS 0.08
- ATRC 0.98
- MACD
- IGMS 0.01
- ATRC -0.10
- Stochastic Oscillator
- IGMS 83.87
- ATRC 36.52
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.